Cooley advised Faeth Therapeutics (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling, on its acquisition by Sensei Biotherapeutics. This acquisition brings Faeth’s lead asset, PIKTOR – a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting – into Sensei’s pipeline.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics